LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

Search

Iovance Biotherapeutics Inc

Abierto

SectorSalud

1.69 -2.87

Resumen

Variación precio

24h

Actual

Mínimo

1.68

Máximo

1.82

Métricas clave

By Trading Economics

Ingresos

-38M

-116M

Ventas

-24M

49M

BPA

-0.36

Margen de beneficio

-235.51

Empleados

838

EBITDA

14M

-75M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+588.83% upside

Dividendos

By Dow Jones

Próximas Ganancias

7 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-524M

644M

Apertura anterior

4.56

Cierre anterior

1.69

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

209 / 382 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

Iovance Biotherapeutics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

13 may 2025, 23:20 UTC

Ganancias

Aristocrat Leisure Boosts Half-Year Dividend, Keeps Focus on M&A

13 may 2025, 23:48 UTC

Charlas de Mercado

Gold Edges Higher, Supported by Signs of Mild U.S. Inflation -- Market Talk

13 may 2025, 23:43 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

13 may 2025, 23:43 UTC

Charlas de Mercado

Nikkei May Rise on Hopes for Improving U.S.-China Trade Relations -- Market Talk

13 may 2025, 23:24 UTC

Charlas de Mercado
Ganancias

Global Equities Roundup: Market Talk

13 may 2025, 23:24 UTC

Charlas de Mercado
Ganancias

Aristocrat's 1H Result Falls Short, Jefferies Says -- Market Talk

13 may 2025, 22:58 UTC

Ganancias

Table: Samsung Fire & Marine 1Q Consolidated Net KRW609.03B Vs KRW701.95B

13 may 2025, 22:58 UTC

Ganancias

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Net KRW609.03B Vs KRW701.95B

13 may 2025, 22:58 UTC

Ganancias

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Op Pft KRW792.36B Vs Op KRW897.06B

13 may 2025, 22:58 UTC

Ganancias

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Rev KRW6.106T Vs KRW5.507T

13 may 2025, 22:38 UTC

Ganancias

Aristocrat: Continues to Actively Pursue Strategic M&A Activities

13 may 2025, 22:38 UTC

Ganancias

Aristocrat: Remains Committed to Capital Management Strategy, Ongoing Share Buy-Back Program

13 may 2025, 22:37 UTC

Ganancias

Aristocrat: Expects More Operating Momentum in 2H Amid Product Rollout, Technology Initiatives

13 may 2025, 22:36 UTC

Ganancias

Aristocrat: Sees Accelerating Performance at Interactive Unit Toward FY 2029 US$1 Bln Revenue Target

13 may 2025, 22:35 UTC

Ganancias

Aristocrat: Expects Continued Market Share Gains from Gaming Unit

13 may 2025, 22:34 UTC

Ganancias

Aristocrat: Expects to Deliver NPATA Growth Over the Full Year on a Constant Currency Basis

13 may 2025, 22:33 UTC

Ganancias

Aristocrat: Interactive Business Delivered Strong Revenue Growth

13 may 2025, 22:33 UTC

Ganancias

Aristocrat: Gaming Unit Continued to Deliver Market Share Gains

13 may 2025, 22:33 UTC

Ganancias

Aristocrat: Product Madness' Key Social Casino Franchises Continued to Outperform

13 may 2025, 22:30 UTC

Ganancias

Aristocrat Interim Dividend 44 Australian Cents/Share

13 may 2025, 22:30 UTC

Ganancias

Aristocrat 1H Statutory Net Profit from Continuing Operations A$511 Mln, Down 21.6%

13 may 2025, 22:29 UTC

Ganancias

Aristocrat 1H Normalized Operating Revenue A$3 Bln, Up 8.7%

13 may 2025, 22:28 UTC

Ganancias

Aristocrat 1H Normalized Net Profit A$733 Mln, Up 5.6%

13 may 2025, 21:15 UTC

Ganancias

Nu Holdings 1Q Rev $3.2B >NU

13 may 2025, 21:03 UTC

Principales Noticias

GOP Mega Bill's Details Are Out. Now the Fighting Begins. -- WSJ

13 may 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

13 may 2025, 20:32 UTC

Ganancias

Alcon Raises 2025 View To Sales $10.4B-$10.5B >ALC.EB

13 may 2025, 20:31 UTC

Ganancias

Alcon 1Q Sales $2.45B >ALC.EB

13 may 2025, 20:30 UTC

Ganancias

Alcon 1Q Rev $2.47B >ALC.EB

13 may 2025, 20:30 UTC

Ganancias

Alcon 1Q EPS 70c >ALC.EB

Comparación entre iguales

Cambio de precio

Iovance Biotherapeutics Inc Esperado

Precio Objetivo

By TipRanks

588.83% repunte

Estimación a 12 meses

Media 12.33 USD  588.83%

Máximo 25 USD

Mínimo 3 USD

De acuerdo con 14 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Iovance Biotherapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

14 ratings

9

Comprar

5

Mantener

0

Vender

Puntuación técnica

By Trading Central

3.0208 / 3.5Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Weak Bearish Evidence

Sentimiento

By Acuity

209 / 382 Clasificación en Salud

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Iovance Biotherapeutics Inc

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.